文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Advancing use of long-acting and extended delivery HIV prevention and treatment regimens.

作者信息

Delany-Moretlwe Sinéad, Flexner Charles, Bauermeister José A

机构信息

Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.

Divisions of Clinical Pharmacology and Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.

出版信息

J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26126. doi: 10.1002/jia2.26126.

DOI:10.1002/jia2.26126
PMID:37439079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10338994/
Abstract
摘要

相似文献

[1]
Advancing use of long-acting and extended delivery HIV prevention and treatment regimens.

J Int AIDS Soc. 2023-7

[2]
Advancing long-acting and extended delivery HIV prevention and treatment regimens through behavioural science: NIH workshop directions.

AIDS. 2021-7-1

[3]
The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.

J Int AIDS Soc. 2023-7

[4]
Long-Acting HIV Drugs for Treatment and Prevention.

Annu Rev Med. 2018-10-24

[5]
Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective.

New Microbiol. 2017-4

[6]
Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.

J Int AIDS Soc. 2023-7

[7]
Long-acting drugs and formulations for the treatment and prevention of HIV infection.

Int J Antimicrob Agents. 2021-1

[8]
Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.

J Int AIDS Soc. 2023-7

[9]
Considerations and challenges in developing novel long-acting antiretrovirals modalities for treatment and prevention of HIV-1 infection: a regulatory perspective.

Curr Opin HIV AIDS. 2020-1

[10]
Delivery of long-acting injectable antivirals: best approaches and recent advances.

Curr Opin Infect Dis. 2015-12

引用本文的文献

[1]
Preferences for Long-Acting HIV Pre-Exposure Prophylaxis among Women of Reproductive Age in Low- and Middle-income Countries: A Systematic Review.

AIDS Behav. 2025-7-21

[2]
Feasibility and acceptability of persons on long-acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study.

J Int AIDS Soc. 2025-7

[3]
Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study.

PLoS One. 2025-2-28

[4]
Current Challenges, Solutions, and Novel Directions in Research and Clinical Care: Proceedings From the 14th Annual International Workshop on HIV and Aging.

J Gerontol A Biol Sci Med Sci. 2024-12-11

[5]
A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035.

J Int AIDS Soc. 2024-3

本文引用的文献

[1]
Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.

J Int AIDS Soc. 2023-7

[2]
Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.

J Int AIDS Soc. 2023-7

[3]
Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.

J Int AIDS Soc. 2023-7

[4]
Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.

J Int AIDS Soc. 2023-7

[5]
The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.

J Int AIDS Soc. 2023-7

[6]
Benefits and limitations of different study designs for long-acting antiretroviral therapy among people living with HIV with viremia.

J Int AIDS Soc. 2023-7

[7]
Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.

J Int AIDS Soc. 2023-7

[8]
Including pregnant and breastfeeding people in trials of novel LAED PrEP agents: perspectives from sub-Saharan Africa community stakeholders.

J Int AIDS Soc. 2023-7

[9]
Implementation and resource needs for long-acting PrEP in low- and middle-income countries: a scoping review.

J Int AIDS Soc. 2023-7

[10]
What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations.

J Int AIDS Soc. 2023-7

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索